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Abstract
Background: Diabetes is a metabolic disorder affecting carbohydrate, fat and protein metabolism.
Tridax procumbens Linn. (Family-Asteraceae; common name-Dhaman grass) is common herb found
in India. Traditionally, the tribal inhabitants of Udaipur district in Rajasthan (India) uses the leaf
powder (along with other herb) orally to treat diabetes. There is a need to evaluate extracts of this
plant in order to provide scientific proof for it's application in traditional medicine system.
Methods: Extraction of whole plant of T. procumbens using 50%methanol. The extract was tested
for acute and sub-chronic anti-hyperglycemic activity in alloxan induced diabetic rats and for acute
toxicity test among normal rats. Observations on body weight as well as on the oral glucose
tolerance levels were also recorded.
Results: Oral administration of acute and sub chronic doses (250 and 500 mg/kg b.wt.) of T.
procumbens extract showed a significant (p < 0.05) reduction in fasting blood glucose levels in
diabetic rats, however the decline in blood sugar levels in normal rats was not observed. In acute
study the maximum percent blood glucose reduction (68.26% at 250 mg/kg and 71.03% at 500 mg/
kg body weight) in diabetic rats was observed at 6 h. The anti-hyperglycemic effects were not
dependent of dose and the OGTT and Body weight supported the antihyperglycemic action of the
drug. The results of anti-diabetic effect of T. procumbens were compared with the reference
standard drug Glibenclamide (10 mg/kg b.wt.).
Conclusion:  These test results support traditional medicinal use of, T. procumbens for the
treatment of diabetes mellitus with corrections in body weight and oral glucose tolerance and no
visible signs or symptoms of toxicity in normal rats indicating a high margin of safety. These results
warrant follow-up through bioassay-directed isolation of the active principles.
Background
Diabetes is a metabolic disorder affecting carbohydrate,
fat and protein metabolism. It is affecting nearly 10% of
the population world wide[1]. The frequency of the diabe-
tes will escalate worldwide, with a major impact on the
population of developing countries[2]. The Current stud-
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ies in India indicate that there is an alarming rise in prev-
alence of diabetes which has gone beyond epidemic form
to a pandemic one[3]. Currently India has got the largest
number of diabetics and is being called as diabetic capital
of the world[4].
The Diabetes Control and Complications Trial (DCCT)
demonstrated that tight control of blood glucose is effec-
tive in reducing clinical complications significantly, but
even optimal control of blood glucose could not prevent
complications suggesting that alternative treatment strate-
gies are needed[5]. The available therapies for diabetes
include insulin and many oral hypoglycemic agents, such
as biguanids and sulfonylureas[6]. Treatment with sulfo-
nylureas and biguanids is also associated with side effects
and fail to significantly alter the course of diabetic compli-
cations[7]. The search for new pharmacologically active
agents obtained by screening natural sources such as
medicinal plants or their extracts has led to the discovery
of many clinically useful drugs that play a major role in
the treatment of human diseases. A number of medicinal
plants and their formulations are used for treating diabe-
tes in folklore/Ayurvedic medicine system as well as in
ethnomedicinal practices[8]. WHO (1980) has also rec-
ommended the evaluation of the plants effective and in
conditions where we lack safe modern drugs[9]. This leads
to increasing demand for herbal products with anti-dia-
betic activity and less side effects.
Tridax procumbens Linn. (Family-Asteraceae; common
name-Dhaman grass) is common herb found in India.
The whole plant and seeds are reported to be used to treat
various aliments, such as bronchial catarrh, dysentery,
diarrhea, preventing hair loss, and to check hemorrhage
from cuts [10,11]. Pharmacological studies have shown
that T. procumbens possess properties like-anti inflamma-
tory, hepatoprotective, wound healing, Immunomodula-
tory, antimicrobial, antiseptic, and hypotensive,
bradycardiac effects [12-16]. Earlier workers [17-20] have
already reported the presence of dexamethasone, luteoline,
glucotureolin, β-sitosterol, flavone, glycoside and quercetin in
this plant. Very little information is available regarding
hypoglycemic/anti-hyperglycemic property of Tridax.
Traditionally, the tribal inhabitants of Udaipur district in
Rajasthan (India) uses the leaf powder (along with other
herb) orally to treat diabetes [21]. Until now no scientific
investigation had been carried out to shed light on the
anti-diabetic, hypoglycemic property of Tridax procum-
bens. Thus, in order to validate the tribal use of the plant
as an anti-diabetic, the objective of the present study was
to study the effects of the methanolic (50%) extract from
whole plant of Tridax procumbens on body weight, Fasting
blood glucose as well as on the oral glucose tolerance lev-
els, in the models of normal and alloxan-induced diabe-
tes, in rats.
Methods
Plant Material
Tridax procumbens, whole plant was collected from the
Udaipur district during the month of September-October,
and was identified and authenticated from the depart-
ment of Botany, University of Rajasthan, Jaipur. A voucher
specimen (RUBL No. 20534) was retained in the Herbar-
ium of the department of Botany, University of Rajasthan,
Jaipur.
Preparation of Extract
The shed-dried plant material was coarsely powdered (6.9
kg) and extracted with 50% methanol using soxhlet appa-
ratus for 36 hrs. The resulting mixture was filtered and the
filtrate was evaporated in an oven at 40°C to get the dry
residue (7.86 g). The resultant residue was used as 'drug'
in experiments.
Chemicals
Alloxan monohydrate was obtained from Sigma Chemi-
cal Co. (St. Louis, MO., USA). Glibenclamide tablets
(Daonil; Aventis Pharma. Ltd., India) were procured from
the authorized distributor of the company. All other
chemicals used were of analytical grade.
Experimental Animals
Adult healthy male albino rats of Wistar strain weighing
140-160 g, obtained from IVARI Izatnagar, Bareli (U.P.)
were used after acclimatization for 14 days for this study.
The animals were housed in polypropylene cages under
standard husbandry conditions (12 hrs light/dark cycle:
25 ± 3°C). Rats were provided water and pellet diet (Hin-
dustan Lever Ltd., Bangalore, India.) ad libitum. The study
was conducted after the approval from the institutional
ethical committee for animal care.
Induction of Experimental Diabetes in Rats
After fasting, diabetes was induced by a single intraperito-
neal injection of 120 mg/kg body weight of 'Alloxan mono-
hydrate' in distilled water. The animals were allowed to
drink 5% glucose solution overnight to overcome the
drug-induced hypoglycemia. These animals were tested
for diabetes after 15 days and animals with blood glucose
(fasting) range 300 - 450 mg/dl were selected for experi-
mentation.
Experimental Protocol
Animals were divided into seven groups of 6 rats each.
Group I: Rats served as normal-control and received
the vehicle (0.5 ml distilled water/day/rat)BMC Complementary and Alternative Medicine 2009, 9:48 http://www.biomedcentral.com/1472-6882/9/48
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Group II: Rats (normal) were administered T. procum-
bens (250 mg/kg b.wt./day) in distilled water as a fine
aqueous suspension orally.
Group III: Rats (normal) were administered T. procum-
bens (500 mg/kg b.wt./day) in distilled water as a fine
aqueous suspension orally.
Group IV: Rats served as diabetic-control and received
the vehicle (0.5 ml distilled water/day/rat)
Group V: Rats (diabetic) were administered T. procum-
bens (250 mg/kg b.wt./day) in distilled water as a fine
aqueous suspension orally.
Group VI: Rats (diabetic) were administered T.
procumbens (500 mg/kg b.wt./day) in distilled water as
a fine aqueous suspension orally.
Group VII: Rats (diabetic) were administered Gliben-
clamide (10 mg/kg b.wt./day) in distilled water as a
fine aqueous suspension orally.
All the rats were fasted for 16 hr. before experimenta-
tion, but allowed free access to water.
Acute Dose Study
All the rats received single dose treatment in all groups.
1. Blood Sugar Estimation: Blood samples were col-
lected by tail vein puncture just prior to drug adminis-
tration and at 1/2, 1, 2, 4, 6 and 8 hrs. The blood
glucose was estimated by 'One touch-ULTRA' glucom-
eter (Johnson & Johnson company, USA).
2. Acute Toxicity Evaluation in Rats: The methanolic
extract was tested for its acute and short-term toxicity
(if any) in normal rats. To determine acute toxicity of
a single oral administration of herbal drug, different
doses of the drug (0.25--5.0 g/kg) were administrated
to different groups of rats (8 rats in each group with 4
male and 4 female). Mortality and general behavior of
the animals were observed periodically for next 48 h.
The animals were observed continuously for the initial
4 h and intermittently for the next 6 h and then again
for 24 h and 48 h after the drug administration. The
parameters observed were grooming, mood, hyperac-
tivity, sedation, loss of righting reflex, respiratory rate
and convolutions.
Sub-chronic Dose study
All the rats received treatment for 30 days in all groups.
1. Body weight: Body weight was measured at the time
of alloxan-dosing. After 15 d of alloxan-dosing, the
body weight of all the rats was measured once a week
with at sacrifice (30 d). Before blood collection and at
sacrifice day experimental animals were overnight
fasted (water was not restricted) to reduce the erratum
of feeding.
2. Fasting Blood Glucose (FBG) Estimation: Fasting
Blood Glucose was measured at the time of alloxan-
dosing. After 15 d of alloxan-dosing, the Fasting Blood
Glucose of all the rats was measured once a week with
at sacrifice (30 d). Blood samples were collected by tail
vein puncture just prior to drug administration and at
7, 15, 21 and 30 days. The blood glucose was esti-
mated by 'One touch-ULTRA' glucometer (Johnson &
Johnson company, USA). The results were expressed
in terms of mg/dl of blood.
3. Oral Glucose Tolerance Test (OGTT): Prior to an
OGTT all the rats were fasted for 16 h Distilled water
(control), a reference drug glibenclamide (10 mg/kg
b.wt.) or each of the two different doses of Tridax
procumbens extract (250 and 500 mg/kg b.wt.) were
then orally administered to respective groups of 6 rats
each. 30 min. later, glucose (3 g/kg) was orally admin-
istered to each rat with a feeding syringe. Blood sam-
ples were collected from the tail vein by tail milking at
-30(just before the extract and glibenclamide adminis-
tration), 0 (just before the oral administration of glu-
cose), 30, 60, 90 and 120 min. after glucose load.
Statistical Analysis
Results were expressed as mean ± SEM. Data were ana-
lyzed with one way ANOVA for the comparison between
groups, followed by Tukey as a post hoc test. The signifi-
cance level was set at p < 0.05.
Results
Acute dose study
1. Effect on Normal Rats
The results of effect oral administration of the
plant extract on normal rats are shown in Table 1.
The effect of both the doses of 50% methanolic
extract of T. procumbens on fasting blood glucose
levels in normal rats were assessed at different time
intervals. 250 mg/kg b.wt. and 500 mg/kg b.wt.
doses of T. procumbens did not cause any signifi-
cant change in blood sugar levels.
2. Effects on Alloxan Induced Diabetic Rats
The results are presented in Table 2 showed that; in
the diabetic rats, the fasting blood glucose levels
were 4-5 times higher than that of the normal rats.
A sharp decline in blood sugar level was observedBMC Complementary and Alternative Medicine 2009, 9:48 http://www.biomedcentral.com/1472-6882/9/48
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from 2nd hour after the treatment in both 250 and
500 mg/kg doses of T. procumbens and also in glib-
enclamide (10 mg/kg) treated rats. The percentage
blood glucose reduction with 250 and 500 mg/kg
doses of T. procumbens and glibenclamide (10 mg/
kg) was observed maximum at 6 h was
68.26,71.03 and 57.29% respectively. Both the
doses of the extract treatment (250 and 500 mg/kg
b.wt.) showed more effective lowering of blood
sugar then the standard drug viz. glibenclamide
(10 mg/kg).
3. Toxicity Evaluation
In the acute toxicity study, the methanolic extract
of T. procumbens did not show any mortality and
none of the treated animal showed any visible
symptoms of toxicity up to a dose of 5 g/kg body
weight. Even at this high dose there was no gross
behavioral changes indicating high margins of
safty.
Sub-chronic dose study
1. Effect on Body weight
The results presented in Table 3; exhibit the
changes of body weight among diabetic and non-
diabetic rats. A normal body weight gain was
observed in Group I, II and III. However, a signifi-
cant decrease of body weight gain was observed at
0 d among the rats dosed with alloxan (Group IV,
V, VI and VII). Thereafter, the treated diabetic ani-
mals showed sign of recovery in body weight gain.
On the contrary, untreated diabetic rats showed a
progressive fall in body weight throughout the
experimental period. Body weight in both the
extract treated daibetic groups was significantly
increased from 15 d after dosing. In glibenclamide
(10 mg/kg) dosing group, no significant changes
compared to that of diabetic control were detected.
2. Effect on Fasting Blood Glucose (FBG) Levels
Table 1: Variation in blood glucose levels after oral administration of T. procumbensin normal rats
Normal Control Normal+ Extract (250 mg/kg) Normal+ Extract (500 mg/kg) Normal+ Glibenclamide (10 mg/kg)
0 h 87.16 ± 0.93a 84.33 ± 0.67a 84.66 ± 0.58a 90.16 ± 1.18a
1/2 h 85.66 ± 1.10a 81.83 ± 1.97a 90.66 ± 1.12a 87.33 ± 1.90a
1 h 88.33 ± 1.90a 87.50 ± 1.18a 89.00 ± 1.05a 84.00 ± 1.10a
2 h 88.16 ± 0.66a 85.50 ± 2.61a 83.33 ± 2.61a 81.66 ± 0.66b
4 h 84.00 ± 0.61a 79.66 ± 1.39a 85.16 ± 0.66a 73.50 ± 1.10b
6 h 85.83 ± 1.05a 81.33 ± 0.61a 82.16 ± 0.93a 62.10 ± 3.60b
8 h 84.00 ± 1.10a 82.50 ± 1.57a 80.83 ± 1.05a 56.18 ± 4.50b
Values represent mean ± SEM (n = 6).
*Values for a given group in a row followed by same letter as superscript are not significantly different according to Tukey's multiple comparison 
procedure (at P < 0.05).
Table 2: Variation in blood glucose levels after oral administration of T. procumbensin alloxan-induced diabetic rats
Normal Control Diabetic Control Diabetic+ Extract 
(250 mg/kg)
Diabetic+ Extract 
(500 mg/kg)
Diabetic+ Glibenclamide 
(10 mg/kg)
0 h 87.16 ± 0.93a 446.60 ± 3.30b 406.80 ± 5.18b 395.60 ± 3.27b 369.70 ± 4.32b
1/2 h 85.66 ± 1.10a 440.10 ± 4.15b 394.60 ± 6.12c 389.12 ± 7.90c 370.50 ± 3.10c
1 h 88.33 ± 1.90a 453.60 ± 4.52b 336.80 ± 12.90c
(17.20)
300.50 ± 10.47c
(24.03)
321.10 ± 4.80c
(13.14)
2 h 88.16 ± 0.66a 436.60 ± 3.90b 313.10 ± 15.04c
(23.03)
289.70 ± 8.05d
(26.76)
264.80 ± 12.66d
(28.37)
4 h 84.00 ± 0.61a 425.30 ± 6.72b 219.70 ± 13.13c
(45.99)
188.00 ± 16.22d
(52.47)
218.10 ± 16.21d
(41.00)
6 h 85.83 ± 1.05a 439.30 ± 3.35b 129.10 ± 11.05c
(68.26)
114.60 ± 9.51c
(71.03)
157.90 ± 10.33d
(57.29)
8 h 84.00 ± 1.10a 447.80 ± 4.50b 132.30 ± 6.23c
(67.48)
119.40 ± 12.87c
(69.81)
209.60 ± 8.02d
(43.31)
Values represent mean ± SEM (n = 6).
*Values for a given group in a row followed by same letter as superscript are not significantly different according to Tukey's multiple comparison 
procedure (at P < 0.05).
Values given in parenthesis are percent blood glucose reduction from the 0 h value in the respective columnBMC Complementary and Alternative Medicine 2009, 9:48 http://www.biomedcentral.com/1472-6882/9/48
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The Table 4 demonstrate the levels of FBG in nor-
mal and alloxan diabetic rats at the time of alloxan
dosing, 0 d (just before the drug administration)
and 7, 15 and 30 days of treatment. Both the doses
of 50% methanolic extract of T. procumbens did not
cause any significant change in fasting blood glu-
cose levels in normal rats. The administration of T.
procumbens extract to diabetic rats resulted in a sig-
nificant decrease in the levels of fasting blood glu-
cose. In T. procumbens treated rats, although a
significant antihyperglycemic effect was evident
from the 7 d onwards, the decrease in FBG was
highly pronounced on 30 d and moved towards
resettlement to the normal level. The antihypergly-
cemic effects of T. procumbens were more promi-
nent than glibenclamide. Administration of the
extract at 500 mg/kg b.wt. dose did not show sig-
nificant variations in FBG when compared to that
of 250 mg/kg b.wt. dose level.
Table 3: Effects of treatment with Tridax procumbens extract on body weight in normal and alloxan diabetic rats.
Group
(n = 6)
Dose
(mg/kg b.wt)
BODY WEIGHT IN GRAMS
Alloxanα) dos-
ing
DAYS AFTER DOSING
0 dβ) 7 d 15 d 21 d 30 dγ)
Normal Control - 162.6 ± 4.2a 201.3 ± 1.9 b 
(23.80)
208.4 ± 2.1b 
(3.52)
217.4 ± 6.2b 
(4.31)
225.8 ± 4.9c 
(3.86)
234.4 ± 7.8 c 
(3.80)
Normal+ 
Extract
250 160.0 ± 3.6a 196.2 ± 2.7 b 
(22.62)
205.5 ± 1.9 b 
(4.74)
213.2 ± 5.4 c 
(3.74)
221.1 ± 3.2 c 
(3.70)
228.6 ± 4.2 c 
(3.39)
Normal+ 
Extract
500 156.1 ± 2.4a 197.6 ± 2.1 b 
(26.58)
205.1 ± 3.0 b 
(3.79)
210.4 ± 4.3 b 
(2.58)
218.3 ± 3.7b 
(3.75)
227.3 ± 2.9c 
(4.12)
Diabetic 
Control
- 156.0 ± 2.9a 163.4 ± 2.8b 
(4.74)
160.4 ± 3.2b -
(1.83)
155.4 ± 4.0 c -
(3.11)
154.6 ± 5.2b -
(0.51)
145.6 ± 5.2c -
(5.82)
Diabetic+ 
Extract
250 157.0 ± 3.1a 164.2 ± 1.7b 
(4.58)
165.4 ± 1.9b 
(0.73)
167.7 ± 2.8b 
(1.39)
176.3 ± 3.2b 
(5.12)
182.6 ± 5.0c 
(3.57)
Diabetic+ 
Extract
500 162.9 ± 2.2a 171.2 ± 1.4b 
(5.09)
173.3 ± 2.1b 
(1.22)
176.5 ± 3.1b 
(1.84)
183.1 ± 2.5b 
(3.73)
189.2 ± 6.4c 
(3.33)
Diabetic+ 
Glibenc-lamide
10 157.3 ± 1.9a 165.3 ± 2.4b 
(5.08)
167.3 ± 3.0b 
(1.20)
168.2 ± 2.8b 
(0.53)
174.0 ± 8.7b 
(2.83)
176.7 ± 3.8b 
(1.55)
Values represent mean ± SEM (n = 6).
*Values for a given group in a row followed by same letter as superscript are not significantly different according to Tukey's multiple comparison 
procedure (at P < 0.05).
α) At alloxan dosing; β) at initial dosing after fasting (15 d after alloxan dosing); γ) at sacrifice after fasting
Values given in parenthesis are percent (%) body weight change compared to previous observation of their respective group
Table 4: Effects of treatment with Tridax procumbens extract on Fasting blood glucose (FBG) in normal and alloxan diabetic rats.
Group
(n = 6)
Dose
(mg/kg)
Alloxaα) dosing Days after dosing
0 dβ) 7 d 15 d 21 d 30 dγ)
Normal Control - 81.21 ± 2.1a 79.00 ± 1.8a 86.12 ± 2.0a 77.45 ± 2.6a 83.20 ± 3.1a 80.16 ± 3.6a
Normal+ Extract 250 78.54 ± 2.4a 77.20 ± 2.6a 79.20 ± 3.5a 76.56 ± 4.8a 75.00 ± 3.5a 76.60 ± 3.0a
Normal+ Extract 500 83.20 ± 1.8a 80.63 ± 3.0a 84.25 ± 2.9a 79.36 ± 6.2a 74.25 ± 5.2a 73.60 ± 5.8b
Diabetic Control - 80.16 ± 1.6a 452.35 ± 4.6b 470.20 ± 6.2b 459.48 ± 11.2b 495.00 ± 9.2c 512.40 ± 9.6c
Diabetic+ Extract 250 82.00 ± 2.8a 454.16 ± 5.4b 299.30 ± 10.2c
(34.09)
215.00 ± 9.6d
(28.16)
186.82 ± 14.7e
(13.10)
171.24 ± 12.5f
(8.33)
Diabetic+ Extract 500 84.40 ± 2.4a 468.20 ± 4.6b 289.50 ± 8.6c
(38.16)
204.20 ± 12.3d
(29.46)
179.42 ± 11.6e
(12.13)
166.00 ± 10.2f
(7.47)
Diabetic+ Glibenc-lamide 10 79.78 ± 2.1a 483.83 ± 6.8b 394.14 ± 9.2c
(18.53)
293.20 ± 14.3d
(25.61)
258.40 ± 12.9e
(11.86)
242.00 ± 11.4e
(6.34)
Values represent mean ± SEM (n = 6).
*Values for a given group in a row followed by same letter as superscript are not significantly different according to Tukey's multiple comparison 
procedure (at P < 0.05).
α) At alloxan dosing; β) at initial dosing after fasting (15 d after alloxan dosing); γ) at sacrifice after fasting
Values given in parenthesis are percent (%) glucose reduction, compared to previous observation of their respective group (in rows)BMC Complementary and Alternative Medicine 2009, 9:48 http://www.biomedcentral.com/1472-6882/9/48
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3. Effect on Oral Glucose Tolerance Test (OGTT)
Table 5 shows the changes in the levels of blood
glucose in normal and diabetic groups after oral
administration of glucose (3 g/kg). The data of
OGTT revealed that the blood glucose levels of the
normal rats reached peak at 60 min after the oral
glucose load and gradually decreased to the pre-
glucose load level. A better glucose tolerance pat-
tern was observed in normoglycemic extract
treated animals, when compared the normal con-
trol rats. In diabetic control group, highly impaired
glucose tolerance was evident. However, in the
extract treated diabetic rats, significant blood glu-
cose attenuation was observed from 60 min
onwards.
Discussion
Alloxan, a beta cytotoxin induces diabetes by free radical
generation, which causes a massive reduction of the insu-
lin secreting β-cells of the islets of langerhans, resulting in
a decrease in endogenous insulin release, which paves the
ways for the decreased utilization of glucose by the tissue
[20]. Glibenclamide is an oral sulphonylurea anti-dia-
betic preparation and widely used as reference drug in
anti-diabetic activity test [21,22].
The data obtained clearly indicate that the acute and sub-
chronic oral administration of T. procumbens extract exhib-
ited only anti hyperglycaemic effects and did not produce
any change in the blood glucose levels of normoglycemic
fasted rats. Further, it was also found that the sub-chronic
treatment with T. procumbens extract for a period of 30
days produced a significant decrease in fasting blood glu-
cose level and improved glucose tolerance of alloxan dia-
betic rats as well as in glucose-loaded normal rats. The
drug showed optimum activity at 250 mg/kg and further
increase in extract dose did not result in a further signifi-
cant decline in blood glucose levels, thus it appears that
unlike insulin and other common hypoglycaemic agents
overdose of the drug may not result in hypoglycemia.
In the acute study, the anti-hyperglycemic action of the T.
procumbens was better (higher in percent and close to nor-
mal range) than that of the standard drug glibenclamide.
The possible mechanism by which T. procumbens brings
about its anti-diabetic action may be by potentiating the
insulin effect of plasma by stimulating insulin release
from the remnant pancreatic β-cells or its release from the
bound form [23]. Beside this, it might involve extra-pan-
creatic action in these alloxan-diabetic rats, which might
include the stimulation of peripheral glucose utilization
or enhancing glycolytic and glycogenic processes with
concomitant decrease in glycogenolysis and gluconeogen-
esis [24]. In the above context a number of other plants
have also shown similar hypoglycemic mechanism [6,25-
28].
In diabetic rats, there was a decline in body weight com-
pared to normal rats. Normal body weight gain is indica-
tor of efficient glucose homeostasis; but in diabetics,
glucose is not available therefore the cells use alternatively
proteins for energy, consequently due to excessive break-
down of tissue protein (muscle wasting) a loss in body
weight occurs. Treatment with T. procumbens induced an
increase in the body weight in diabetic rats, which can be
attributed to the improvement in insulin secretion and
glycemic control. Similar effect on body weight gain was
previously reported with other plants, well known for
their anti-diabetic activity[29].
The antihyperglycemic activity of T. procumbens might be
due to individual or synergistic activity of flavonoids and
other active phytoconstituents of the plant.
Table 5: Effects of treatment with Tridax procumbens extract on oral glucose tolerance (OGTT) after 30 days of drug administration 
in normal and alloxan diabetic rats.
Group
(n = 6)
Dose
(mg/kg b wt)
Blood Glucose levels (mg/dl)
-30 min 0 min 30 min 60 min 90 min 120 min
Normal Control - 79.12 ± 2.8a 80.16 ± 3.6a 146.5 ± 9.6b 152.4 ± 8.4b 121.6 ± 21.6c 102.3 ± 32.0d
Normal+ Extract 250 78.54 ± 4.1a 76.60 ± 3.0a 151.0 ± 11.7b 143.6 ± 9.6b 119.2 ± 16.3c 87.5 ± 12.3d
Normal+ Extract 500 79.58 ± 3.2a 73.60 ± 5.8a 149.4 ± 8.2b 136.6 ± 11.0c 120.6 ± 11.6c 84.6 ± 19.0d
Diabetic Control - 508.2 ± 4.7a 512.40 ± 9.6a HIb 597.2 ± 3.4b 580.6 ± 32.0b 547.5 ± 9.2c
Diabetic+ Extract 250 186.6 ± 2.4a 181.24 ± 12.5a 299.8 ± 43.0b 261.0 ± 34.2c 196.4 ± 14.9d 169.6 ± 14.4e
Diabetic+ Extract 500 163.0 ± 6.8a 165.00 ± 10.2a 302.4 ± 19.6b 271.0 ± 18.3c 190.4 ± 28.4d 160.3 ± 18.4e
Diabetic+ Glibenc-lamide 10 190.4 ± 4.6a 190.00 ± 11.4a 285.6 ± 46.0b 256.6 ± 29.4c 231.0 ± 17.2c 199.6 ± 10.3d
Values represent mean ± SEM (n = 6).
*Values for a given group in a row followed by same letter as superscript are not significantly different according to Tukey's multiple comparison 
procedure (at P < 0.05).
HI = High Blood Glucose Level i. e. above 600 mg/dlBMC Complementary and Alternative Medicine 2009, 9:48 http://www.biomedcentral.com/1472-6882/9/48
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On the basis of the current investigation it was noted that
the methanolic extract of T. procumbens acted in a similar
fashion to glibenclamide (standard drug) and it can be
suggested that these results provide pharmacological evi-
dence for its folklore claim as an anti-diabetic agent.
Conclusion
From the present study, it is concluded that Tridax procum-
bens may be useful in treating diabetes mellitus with no
visible signs or symptoms of toxicity in normal rats indi-
cating a high margin of safety. The 50% methanolic
extracts of Tridax procumbens have indicated high level of
anti-diabetic activity. The extracts exhibited anti-hypergly-
cemic activity comparable to that of a standard anti-dia-
betic drug, glibenclamide. The traditional use of Tridax
procumbens to treat diabetes is supported by laboratory
results from this study, suggesting a need to isolate and
evaluate active constituents responsible for the exhibited
biological activity.
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